Literature DB >> 28959130

Efficacy of Norethisterone in Patients with Ovarian Endometrioma.

Fuminori Taniguchi1, Akiko Enatsu2, Ai Ikebuchi1, Emiko Yamane1, Maako Moriyama1, Jiro Murakami1, Takashi Harada1, Tasuku Harada1.   

Abstract

Endometriosis is a chronic inflammatory disorder associated with pelvic pain and infertility. Because surgical and medical therapies control symptoms, but it is hard to cure completely endometriosis, long term of pharmacologic management is necessary. Norethisterone (NET), one of progestins, has safety profile and advantage that allow long-term use. In this preliminary report, we showed the efficacy of NET in 6 patients with endometriosis. The size of ovarian endometrioma was decreased after treatment with NET for 6 months, and all patients were relieved from dysmenorrhea pain within 6 months, suggesting that NET would be a suitable medication to treat endometriosis.

Entities:  

Keywords:  endometriosis; norethisterone; progestin

Year:  2017        PMID: 28959130      PMCID: PMC5611474     

Source DB:  PubMed          Journal:  Yonago Acta Med        ISSN: 0513-5710            Impact factor:   1.641


  11 in total

Review 1.  Progesterone and bone: a closer link than previously realized.

Authors:  V Seifert-Klauss; M Schmidmayr; E Hobmaier; T Wimmer
Journal:  Climacteric       Date:  2012-04       Impact factor: 3.005

2.  Effect of long-term combined oral contraceptive pill use on endometrial thickness.

Authors:  Nayana Talukdar; Yaakov Bentov; Paul T Chang; Navid Esfandiari; Zohreh Nazemian; Robert F Casper
Journal:  Obstet Gynecol       Date:  2012-08       Impact factor: 7.661

3.  Management of endometriosis with oral medroxyprogesterone acetate.

Authors:  K S Moghissi; C R Boyce
Journal:  Obstet Gynecol       Date:  1976-03       Impact factor: 7.661

Review 4.  The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis.

Authors:  Kristof Chwalisz; Eric Surrey; Frank Z Stanczyk
Journal:  Reprod Sci       Date:  2012-03-27       Impact factor: 3.060

5.  Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma.

Authors:  Fuminori Taniguchi; Akiko Enatsu; Ikuko Ota; Toshiko Toda; Kazuya Arata; Tasuku Harada
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2015-06-16       Impact factor: 2.435

6.  Effect of norethindrone acetate in the treatment of symptomatic endometriosis.

Authors:  O Muneyyirci-Delale; M Karacan
Journal:  Int J Fertil Womens Med       Date:  1998 Jan-Feb

7.  Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial.

Authors:  Tasuku Harada; Mikio Momoeda; Yuji Taketani; Hiroshi Hoshiai; Naoki Terakawa
Journal:  Fertil Steril       Date:  2007-12-27       Impact factor: 7.329

8.  Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study.

Authors:  Paolo Vercellini; Benedetta Bracco; Paola Mosconi; Anna Roberto; Daniela Alberico; Dridi Dhouha; Edgardo Somigliana
Journal:  Fertil Steril       Date:  2015-12-08       Impact factor: 7.329

9.  Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis.

Authors:  S Telimaa; J Puolakka; L Rönnberg; A Kauppila
Journal:  Gynecol Endocrinol       Date:  1987-03       Impact factor: 2.260

10.  Patterns of and risk factors for recurrence in women with ovarian endometriomas.

Authors:  Xishi Liu; Lei Yuan; Fanghua Shen; Zhilin Zhu; Hongyuan Jiang; Sun-Wei Guo
Journal:  Obstet Gynecol       Date:  2007-06       Impact factor: 7.661

View more
  1 in total

1.  Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure.

Authors:  Fernando M Reis; Larissa M Coutinho; Silvia Vannuccini; Frédéric Batteux; Charles Chapron; Felice Petraglia
Journal:  Hum Reprod Update       Date:  2020-06-18       Impact factor: 15.610

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.